Profile data is unavailable for this security.
About the company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
- Revenue in USD (TTM)420.00k
- Net income in USD-22.76m
- Incorporated1996
- Employees12.00
- LocationCyclacel Pharmaceuticals Inc200 Connell Dr Ste 1500BERKELEY HEIGHTS 07922-2811United StatesUSA
- Phone+1 (908) 517-7330
- Fax+1 (866) 271-3466
- Websitehttps://cyclacel.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yield10 Bioscience Inc | 60.00k | -14.46m | 3.33m | 29.00 | -- | -- | -- | 55.45 | -2.09 | -2.09 | 0.0076 | -0.2064 | 0.01 | -- | 4.00 | 2,068.97 | -241.08 | -91.26 | -524.02 | -108.09 | -- | -- | -24,091.67 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
Panacea Life Sciences Holdings Inc | 2.38m | -8.02m | 3.33m | 40.00 | -- | -- | -- | 1.40 | -0.4882 | -0.4882 | 0.145 | -0.4699 | 0.1273 | 1.53 | 10.15 | 59,624.00 | -42.78 | -69.04 | -543.23 | -225.03 | -171.48 | -181.62 | -336.08 | -505.41 | 0.0331 | -2.09 | 3.29 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
Geovax Labs Inc | 0.00 | -25.97m | 3.35m | 17.00 | -- | 0.4974 | -- | -- | -14.25 | -14.25 | 0.00 | 2.91 | 0.00 | -- | -- | 0.00 | -127.82 | -108.34 | -160.47 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Aptevo Therapeutics Inc | 0.00 | -18.65m | 3.45m | 40.00 | -- | 0.0348 | -- | -- | -77.09 | -70.57 | 0.00 | 27.62 | 0.00 | -- | -- | 0.00 | -63.16 | -47.16 | -86.49 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
Applied DNA Sciences Inc | 9.00m | -7.29m | 3.48m | 53.00 | -- | 0.6503 | -- | 0.3866 | -10.91 | -10.91 | 13.56 | 6.20 | 0.5956 | 13.13 | 3.99 | 169,733.00 | -48.39 | -88.57 | -59.91 | -121.91 | 37.65 | 44.35 | -81.25 | -113.26 | 1.63 | -- | 0.00 | -- | -26.43 | 27.92 | -18.73 | -- | 33.80 | -- |
Cyclacel Pharmaceuticals Inc | 420.00k | -22.76m | 3.49m | 12.00 | -- | 4.62 | -- | 8.32 | -26.72 | -26.72 | 0.4924 | 0.5732 | 0.0228 | -- | 0.1106 | -- | -122.40 | -57.58 | -212.95 | -69.81 | -- | -- | -5,370.24 | -18,789.29 | -- | -170.83 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
Phio Pharmaceuticals Corp | 0.00 | -10.83m | 3.50m | 8.00 | -- | 0.369 | -- | -- | -6.40 | -6.40 | 0.00 | 2.06 | 0.00 | -- | -- | 0.00 | -97.63 | -71.92 | -116.38 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
Navidea Biopharmaceuticals Inc | 610.00 | -8.81m | 3.50m | 11.00 | -- | -- | -- | 5,742.55 | -0.2086 | -0.0547 | 0.00001 | -0.0327 | 0.0001 | 0.1529 | 0.0066 | 55.45 | -143.97 | -169.68 | -- | -753.52 | -8,103.28 | 91.34 | -1,411,062.00 | -1,938.53 | 0.5066 | -- | -- | -- | -87.65 | -48.49 | -46.75 | -- | 63.23 | -- |
Revelation Biosciences Inc | 0.00 | -120.25k | 3.51m | 9.00 | 0.0734 | 0.0856 | -- | -- | 29.29 | 29.29 | 0.00 | 25.13 | 0.00 | -- | -- | 0.00 | -1.36 | -- | -3.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
Scisparc Ltd | 0.00 | -6.96m | 3.54m | 3.00 | -- | 39.84 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 3.55m | 25.00 | -- | -- | -- | 0.2253 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
Atreca Inc | 0.00 | -97.76m | 3.56m | 90.00 | -- | 0.3307 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
Optimus Healthcare Services Inc | 1.27m | -7.79m | 3.60m | 17.00 | -- | -- | -- | 2.84 | -0.1948 | -0.1948 | 0.0317 | -0.1291 | 0.2595 | -- | 2.16 | 74,453.53 | -159.79 | -- | -2,228.37 | -- | 77.90 | -- | -615.77 | -- | 0.1525 | -15.41 | 21.18 | -- | -- | -- | -- | -- | -- | -- |
Biostax Corp | 0.00 | -1.65m | 3.60m | -- | -- | -- | -- | -- | -0.0198 | -0.0198 | 0.00 | -0.0456 | 0.00 | -- | -- | -- | -193.36 | -75.14 | -- | -- | -- | -- | -- | -- | -- | -8.97 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
Altamira Therapeutics Ltd | 0.00 | -7.94m | 3.63m | 10.00 | -- | 0.3393 | -- | -- | -16.17 | -8.60 | 0.00 | 4.77 | 0.00 | 34.05 | 32.30 | 0.00 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -- | -- | 1.38 | -4.37 | 0.00 | -- | -- | -- | 61.02 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Altium Capital Management LPas of 31 Dec 2023 | 37.98k | 2.88% |
Acadian Asset Management LLCas of 31 Dec 2023 | 24.22k | 1.84% |
Point72 Asset Management LPas of 31 Dec 2023 | 15.33k | 1.16% |
Renaissance Technologies LLCas of 31 Dec 2023 | 14.44k | 1.10% |
McIlrath & Eck LLCas of 31 Dec 2023 | 832.00 | 0.06% |
Tower Research Capital LLCas of 31 Dec 2023 | 807.00 | 0.06% |
Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2023 | 126.00 | 0.01% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 80.00 | 0.01% |
Wells Fargo Clearing Services LLCas of 31 Dec 2023 | 33.00 | 0.00% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 25.00 | 0.00% |